ATALANTE-1: anti-cancer vaccination after IO failure

OSE-2101 is an anti-cancer vaccine with modified neoepitopes restricted to HLA-A2+ targeting the tumor-associated antigens CEA, p53, HER2, MAGE-2 and MAGE-3 that are frequently expressed in lung cancer [1]. HLA-A2 is assessed in the serum and is positive in approximately half of patients. The randomized, phase III ATALANTE-1 trial tested OSE-2101 in patients with HLA-A2–positive, advanced or metastatic NSCLC who had experienced failure to combined or sequential platinum-based chemotherapy and immunotherapy. Immunotherapy had been administered in the most recent line and had failed due to primary or secondary resistance. Six subcutaneous injections of OSE-2101 were given Q3W followed by Q8W injections for up to year 1 and then 12-weekly injections until progression, while treatment in the control arm consisted of single-agent docetaxel or pemetrexed Q3W until progression. OSE-2101 gave rise to an OS benefit in 103 patients, with 1-year rates of 46 % vs. 36 % (HR, 0.71) [2]. However, due to the COVID-19 pandemic, the study was stopped in April 2020, and a population of interest was identified for further analyses. This comprised 118 patients who had secondary resistance to immunotherapy after sequential chemo-immunotherapy. At ESMO 2021, Besse et al. presented the results of the final primary analysis performed in this group [3].

Indeed, the cancer vaccine gave rise to statistical OS improvement with a meaningful median survival gain of 3.6 months (11.1 vs. 7.5 months; HR, 0.59; p = 0.017). Moreover, OSE-2101 treatment resulted in significantly longer post-progression survival (7.7 vs. 4.6 months; HR, 0.46; p = 0.004). The disease control rates at 6 months were similar across the two arms (25 % vs. 24 %; p = 0.87), which also applied to median PFS (2.7 vs. 3.2 months; p = 0.40). OSE-2101 was well tolerated, with a lower rate of treatment-related grade 3-5 AEs (11 % vs. 35 %). Administration site reactions occurred most commonly in the experimental arm (all grades, 39 %). Cytokine release syndrome was observed in 8 %, including one grade 3 event (1 %). The vaccine induced significant improvements in time to worsening to ECOG performance status ≥ 2 (8.6 vs. 3.3 months; HR, 0.45; p = 0.0005) and quality of life according to the EORTC QLQ-C30 questionnaire (p = 0.04). In their conclusion, the authors noted that OSE-2101 demonstrated a favorable benefit-risk ratio vs. chemotherapy in a setting that is characterized by a lack of therapeutic alternatives.

REFERENCES

  1. Beebe M et al., Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy. Hum Vaccin 2008; 4(3): 210-218
  2. Giaconne G et al., Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer patients after failure to immune checkpoint inhibitors: Step 1 results of phase III ATALANTE-1 randomised trial. ESMO 2020 1260M0
  3. Besse B et al., Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer patients after failure to immune checkpoint inhibitors: final results of phase 3 Atalante-1 randomised trial. ESMO 2021, LBA47

© 2021 Springer-Verlag GmbH, Impressum

More posts

ATALANTE-1: anti-cancer vaccination after IO failure

OSE-2101 is an anti-cancer vaccine with modified neoepitopes restricted to HLA-A2+ targeting the tumor-associated antigens CEA, p53, HER2, MAGE-2 and MAGE-3 that are frequently expressed in lung cancer. HLA-A2 is assessed in the serum and is positive in approximately half of patients.

Gradual progress in the management of mesothelioma and thymoma

This is an important field where little progress has been made in the past. At ESMO 2021, updated results of the randomized CheckMate-743 trial of nivolumab plus ipilimumab versus chemotherapy were presented by Prof. Peters. The overall survival benefit was pronounced in patients with PD-L1–positive or non-epithelioid mesotheliomas, although there was an OS benefit in the total population.

Malignant pleural mesothelioma: immunotherapy-based approaches in all treatment lines

The randomized phase III CheckMate 743 trial evaluated nivolumab 3 mg/kg Q2W plus ipilimumab 1 mg/kg Q6W for up to 2 years compared with cisplatin or carboplatin plus pemetrexed Q3W for 6 cycles as first-line treatment of patients with unresectable malignant pleural mesothelioma (MPM). More than 300 patients were randomized into each study arm.

Small-cell lung cancer: on the road to improved efficacy and tolerability

Lurbinectedin, a selective inhibitor of oncogenic transcription, has been approved at a dose of 3.2 mg/m2 Q3W for the treatment of patients with small-cell lung cancer (SCLC) showing disease progression on or after platinum-based chemotherapy in the US. The randomized, phase III ATLANTIS trial tested the combination of lurbinectedin 2 mg/m2 and doxorubicin 40 mg/m2 Q3W for a maximum of 10 cycles followed by lurbinectedin 3.2 mg/m2 Q3W in 307 patients with relapsed SCLC after one prior chemotherapy line.

Immunotherapy: boosting efficacy and overcoming resistance

The global, randomized, open-label, phase III POSEIDON trial evaluated the PD-L1 inhibitor durvalumab with or without the anti-CTLA-4 antibody tremelimumab in addition to chemotherapy as a first-line strategy in the setting of metastatic NSCLC. At 153 sites in 19 countries, 1,013 patients with squamous or non-squamous, stage IV NSCLC were randomized into three arms.

Innovative and established agents across a range of targets

HER2 mutations constitute the predominant driver aberration in approximately 3 % of non-squamous NSCLC cases. While approved HER2-targeted therapies for patients with NSCLC are still lacking, the anti-HER2 antibody-drug conjugate trastuzumab deruxtecan (T-DXd) has been licensed in various countries for use in other HER2-positive entities.